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A hallmark of aging is a decline in metabolic homeo-
stasis, which is attenuated by dietary restriction (DR).
However, the interaction of aging and DR with the
metabolome is not well understood. We report that
DR is a stronger modulator of the rat metabolome
than age in plasma and tissues. A comparative me-
tabolomic screen in rodents and humans identified
circulating sarcosine as being similarly reduced
with aging and increased by DR, while sarcosine is
also elevated in long-lived Ames dwarf mice.
Pathway analysis in aged sarcosine-replete rats
identify this biogenic amine as an integral node in
the metabolome network. Finally, we show that sar-
cosine can activate autophagy in cultured cells and
enhances autophagic flux in vivo, suggesting a po-
tential role in autophagy induction byDR. Thus, these
data identify circulating sarcosine as a biomarker of
aging and DR in mammalians and may contribute
to age-related alterations in the metabolome and in
proteostasis.
INTRODUCTION
An overall decline in metabolic homeostasis is a hallmark of ag-
ing across mammalian species (Barzilai et al., 2012). We and
others have shown that visceral and ectopic fat accrual, subcu-
taneous fat depletion, hyperlipidemia, and insulin resistance are
characteristic age-related changes in rodents and humans (Bar-
zilai et al., 2012; Cartier et al., 2009; Johannsen et al., 2012). In
spite of these well-recognized gross metabolic manifestations,
our understanding of how shifts in specificmetabolites and path-
ways are affected by aging, as well as by age-delaying strategies
such as dietary restriction (DR), has only recently begun to be
elucidated.
An early metabolomic study using 4- and 22-month-old male
C57BL/6 mice reported that aging was characterized by altered
glucose and fatty acid metabolism, including a lower respiratory
exchange ratio (RER), increased plasma fatty acids, and reduc-
tions in triglycerides (TGs), various amino acids, and acylcarni-
tines (Houtkooper et al., 2011). In another study using older fe-
male C57BL/6 mice, it was reported that DR opposed a
significant number of identified age-related changes in lipid
metabolism, fatty acid metabolism, and bile acid biosynthesis
(De Guzman et al., 2013), suggesting that at least some age-
related shifts in the metabolome can be prevented.
The metabolomic profile of aging has also been assessed in a
number of other species, including Drosophila melanogaster
(Hoffman et al., 2014), naked mole rat (Mitchell et al., 2007),
marmoset (Hoffman et al., 2016), and humans (Cheng et al.,
2015). Tissue-specific metabolomic signatures were reported
to correlate with body mass and lifespan across a diverse num-
ber of species, and some tissue metabolites were found that
discriminated long-lived rodents from controls (Ma et al.,
2015). Although data on metabolomic shifts with aging and diet
Cell Reports 25, 663–676, October 16, 2018 ª 2018 The Authors. 663
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
are rapidly accumulating, replication across studies has been
limited, which has slowed progress toward ascertaining
consensus hallmark candidates and signatures that define the
aging metabolome across sex, strain, and species. Furthermore,
to what extent these metabolomic shifts are merely a conse-
quence of aging per se, as opposed to playing a causal role in
the aging process, has been difficult to discern from what has
largely been observational data.
Here, we have characterized changes in the metabolome with
aging and DR using established techniques in plasma and mul-
tiple tissues from a well-characterized hybrid rat model of aging.
We have also interrogated the metabolome for shared changes
in a set of human samples obtained from a cohort of younger
and older subjects consuming a Western or DR diet (Meyer
et al., 2006; Soare et al., 2011; Stein et al., 2012). We report on
some unique shifts in the metabolome, including alterations in
glycerophospholipids, biogenic amines, and amino acids with
diet and age. In addition, statistical analyses revealed that DR
is a stronger driver of the circulating and tissue rat metabolomic
phenotype than age.
When screening for metabolites with similar responses be-
tween species, we identified circulating sarcosine, a biogenic
amine involved in methionine (Met), glycine, and folate meta-
bolism, as decreased with aging per se in rodents and humans
and increased by DR in both species. These shifts correlated
with changes in rat liver glycine-N-methyltransferase (GNMT)
content, which is a known sarcosine-generating enzyme. Long-
lived Ames dwarf mice demonstrate significantly elevated sarco-
sine levels across age, while correlation analysis of metabolites
following sarcosine refeeding in old rats prominently places this
metabolite as an integral node linking amines, amino acids, glyc-
erophospholipids, and sphingolipids. We also show that sarco-
sine feeding reduces Met levels in old animals and is a strong
activator of macroautophagy in vitro and in vivo. Taken together,
thesedata identify sarcosine as apotentially important biomarker
of diet and aging in mammals and suggest that this metabolite
plays a previously unappreciated role in mediating at least
some of the beneficial effects attributed to DR on proteostasis.
RESULTS
DR Is a Stronger Modulator of the Rat Metabolic
Phenotype than Age
We first characterized themetabolic phenotype of young and old
ad libitum (AL) and DR Fischer 3443 Brown Norway (FBN) male
rats (abbreviated YAL, OAL, YDR, and ODR, respectively) (Fig-
ure 1). OAL animals had increased body mass with age and
weighed more than age-matched DR rats (Figure 1A; p < 0.05),
along with a tendency toward greater amounts of lean body
mass (Figure 1B; age p = 0.025, diet p < 0.001, interaction p =
0.098) and adiposity (Figure 1C; p < 0.05). By design, DR animals
consumed 40% fewer calories than AL animals (Figure 1D; age
p = 0.18, diet p < 0.001, interaction p = 0.18) and had a lower ab-
solute energy expenditure (EE) (Figure 1E; age p = 0.082, diet p <
0.001, interaction p = 0.69), while 24 hr EE was maintained at
youthful levels after adjusting for lean body mass (LBM) (Fig-
ure 1F; interaction p = 0.029). Substrate utilization in FBN rats
was modulated over time by aging (age 3 time p = 0.019) and
diet (diet 3 time p < 0.001), as demonstrated by disparate sub-
strate utilization between AL and DR animals, particularly during
the dark phase (Figure 1G, red box). In response to an overnight
fast, YAL and OAL animals demonstrated a rapid and significant
fall in RER (<0.7), suggesting a severe shift away from carbohy-
drate utilization and heavy reliance on fat and ketone meta-
bolism, while DR animals were better able to handle this provo-
cation, irrespective of age (Figure 1G, green box; p < 0.05). No
difference in spontaneous activity (Figure 1H) or plasma glucose
(Figure 1I) was observed, but OAL animals tended to be hyperin-
sulinemic (Figure 1J; age p < 0.001, diet p < 0.001, interaction
p = 0.40) and had increased plasma TGs (Figure 1K; p < 0.05).
Free fatty acid (FFA) levels were similar (Figure 1L). However,
glycerol was increased in YDR as compared to YAL animals,
while ODR animals demonstrated lower levels than controls
(Figure 1M; p < 0.05).
Effect of Aging and DR on the Circulating and Tissue
Metabolome
We next assessed changes at the level of the metabolome with
aging and DR in rat plasma, brown adipose tissue (BAT), skel-
etal muscle (SkM), and liver as well as human serum. Specif-
ically, we compared the slopes of age and diet on all metabolite
levels, as determined by the b values obtained from Equation 1
(see Method Details) to specifically test whether diet could
attenuate the effect of age on each metabolite. While a few
weak associations were observed, no strong relations were
found for any of these analyses (Figure 2A). However, we
observed that the majority of significant changes in individual
metabolites were attributed to DR alone (Figure 2A, blue dots),
with far fewer metabolites affected by only age (Figure 2A, red
dots) or by both diet and age (Figure 2A, green dots). We also
asked whether the sign and strength of the effect of diet or of
age on each of the metabolites measured in one tissue was
associated with the effect in other tissues. We found that the ef-
fect of diet on metabolites, as measured by b values, was highly
correlated across tissues. In contrast, the effect of age on
metabolite levels appears to be highly tissue specific (Figure 2B).
We also found that the effect of diet on metabolite levels in hu-
man serum and rat plasma was significantly and positively
correlated (p < 0.01).
The Aging Rat Metabolome Is Defined by an Increase
in Circulating Glycerophospholipids
Reductions in various amino acids, acylcarnitines, and other fatty
acids were previously reported to define the aging mouse blood
metabolome (Houtkooper et al., 2011); thus, we evaluated these
metabolites in our experimental model. Principal-component
analysis (PCA) in rat plasma illustrated that themetabolomic pro-
files for YAL andOAL are distinct. PC1, which separates YAL and
OAL samples, is heavily influenced by changes in glycerophos-
pholipids (Figure 3A). Indeed, we observed a generalized, signif-
icant increase in many glycerophospholipids; amino acids such
as proline (Pro) (p = 0.007; false discovery rate [FDR] a = 0.05),
threonine (Thr) (p = 1.35 3 105), glycine (Gly) (p = 0.028), and
alanine (Ala) (p = 0.024); the acylcarnitine C14:1 (p < 0.001);
and approximately half of the detected sphingolipids in rat
plasmawith aging per se (Figure 3B; Table S1). A similar increase
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in the sphingolipid SM.C16:1 (p = 0.0008), the acylcarnitineC16:1
(p = 0.05, but non-significant [NS] after FDR correction), and
lysoPCaC16:0 (p = 0.039) were observed with age per se
in humans, while lysoPCaC17:0 (p = 0.0016), lysoPCaC18:2
(p = 0.011; FDR a = 0.2), lysoPCaC20:3 (p = 0.0002; FDR a =
0.05), and lysoPCaC20:4 (p = 0.0014) were downregulated with
age per se in human serum (Table S2).
Lifelong DR Opposes the Age-Related Increase in
Several Plasma Metabolites
We next determined to what extent the observed shifts in metab-
olites were an inevitable consequence of aging or whether these
alterations were modifiable by lifelong DR. While comparing the
slopes of age and diet on all of the metabolites did not suggest a
strong effect of DR on age (Figure 2A), PCA clearly demonstrates
that YDR and ODR metabolomic profiles cluster together, irre-
spective of age (Figure 3A). DR opposed the age-related increase
in nearly half of the detected glycerophospholipids and sphingoli-
pids (interactionFDRa=0.05 for themajority ofmetabolites) anda
minorityof aminoacids (glutamine [Gln] [interactionp=0.009;FDR
a = 0.05] and arginine [Arg] [p = 0.02]) and acylcarnitines (C14:1
[p = 0.0009] and C3 [p = 0.0014]) (Figures 3C and 3D). In addition,
a small metabolite screen by gas chromatography-mass spec-
trometry (GC-MS) determined that a minority of other metabolites
found to increase in rat plasma with aging, including ribose
5-phosphate (interaction p= 9.133 106; FDRa=0.05), dehydro-
epiandrosterone (interaction p = 1.773 105), and glycerolphos-
phate (interaction p = 0.0018), were maintained at youthful levels
by lifelong DR (Table S1). However, DR did not significantly pre-
vent age-related changes in 3-hydroxybutyric acid, pyrophos-
phate, or tetradecanoic acid.
In humans, only a limited number of effects were congruent
with those found in rodents (Figure S1; Table S2). For instance,
glutamic acid, which did not change with age in either species,
was similarly reduced by DR in rodents (p = 0.0006; FDR
a = 0.05) and humans (p = 0.0001; FDR a = 0.05). However, a
number of other metabolites identified as changing in rodents,
were either not altered in humans or presented with disparate re-
sults. While circulating glycerophospholipids were robustly and
consistently elevated in OAL rat plasma, a more modest number
of glycerophospholipids were affected by age in human serum
(lysoPCaC17:0, lysoPCaC18:1, lysoPCaC18:2, lysoPCaC20:3,
lysoPCaC20:4, lysoPCaC28:0, and lysoPCaC32:0), and these
metabolites tended to be reduced rather than increased with
Figure 1. Phenotypic Characteristics of Young and Old AL-Fed and DR Rats
(A–D) Total body mass (A), but not LBM (B), were increased with aging, while fat mass was also increased with age (C), which was prevented by lifelong DR to
60% of AL intake (D) (n = 8 per group).
(E and F) Energy expenditure tended to be reduced in young and old DR rats (E), but adjusting for LBM revealed a preservation in metabolic rate with DR (F)
(n = 8 per group).
(G and H) Substrate utilization wasmeasured during a 24-hr light and dark photoperiod, as well as in response to an overnight fast. As indicated in the red box, DR
per se led to a lower RER, particularly during the dark photoperiod, a time in which DR mice are fasted, while RER did not vary with age in AL-fed groups (G).
However, an overnight fast resulted in amore severe reduction in RER for AL animals than those on DR. Furthermore, no difference was observed in spontaneous
activity among groups (H) (n = 8 per group).
(I–K) Fasting glucose levels (I) were similar among groups, but OAL animals tended to have elevated insulin levels (J) and significantly increased TG levels (K),
which were prevented by lifelong DR (n = 8 per group).
(L and M) Plasma FFA levels did not vary among groups (L), but free glycerol was markedly elevated in YDR and OAL, respectively (M) (n = 8 per group). Glucose
and insulin were measured in duplicate, and FFA, TG, and glycerol were assessed in triplicate. Bars and lines represent means ± SEMs. Different letters denote a
significant difference between groups, p% 0.05.
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age. Likewise, the acylcarnitine C14:1 was reduced with human
aging (interaction p = 0.001; FDR a = 0.2) and tended to be main-
tained by DR, while C14:1 levels in rodents increased with aging
and were reduced by DR. Discrepant effects were also observed
with DR per se between species. The longer-chain glycerophos-
pholipids (PCaeC42:1, PCaeC42:2, and PCaeC42:3) tended to
be increased in humans engaged in long-term DR, but the
same metabolites in rodents were increased with age rather
than with DR.
Some Age-Related Perturbations to the Rat BAT
Metabolome Are Attenuated by DR
We next assessed themetabolome in rat BAT. Similar to plasma,
PC1 demonstrates a very strong effect of diet on the BATmetab-
olome, clearly separating the AL and DR groups. As with plasma,
there is a smaller effect of age in BAT, although the effect of age
is more clearly visualized in AL versus DR groups (Figure S2A). In
contrast to plasma, robust reductions were noted for some
amino acids (citrulline [Cit], Gly, Gln, and histidine [His]) and
several glycerophospholipids, sphingolipids, and biogenic
amines, all of which characterized the age-related metabolomic
footprint in this tissue, although very few acylcarnitines were
affected (p < 0.05; Figure S2B; Table S3). DR robustly counter-
acted age-related changes in several BAT metabolites, particu-
larly glycerophospholipids, and tended to preserve Cit and His
levels (FDR a = 0.2), but not other amino acids. DR per se also
resulted in marked effects on some metabolites,
which resembled changes observed with age per se, including
elevated levels of PCaaC34:1, PCaa36:3, and SM.C24:0 and
lower levels of spermidine (Figure S2; Table S3).
Diverse Changes in Rat SkM and Liver Metabolites
with Aging and DR
In ratgastrocnemiusmuscle (SkM),PC3 revealedastrongeffectof
age on the metabolome, particularly glycerophospholipids and
lysine (Lys), Arg, carnosine, and C4, but DR attenuated much of
theageeffecton themetabolomicprofile in this tissue (FigureS3A).
A significant effect of age was observed for several amino acids
analyzed, including Arg, asparagine (Asn), His, Lys, ornithine
(Orn), Pro, and serine (Ser) (FDR a = 0.05), as were the biogenic
amines carnosine (p = 0.001), kynurenine (p = 0.007), and sarco-
sine (p = 0.014) (Figure S3B; Table S4). Several glycerophospholi-
pids were also perturbed in aged SkM, with some metabolites,
including lysoPCaC16:0 (p = 0.001; FDR a = 0.05) and PCaaC34.3
(p = 0.014), generally increased with age. However, several
longer, more unsaturated glycerophospholipids, including
PCaaC36:5 (p = 0.005), PCaaC36:6 (p = 0.001), PCaaC38:6
(p = 1.823 106), and PCaaC40:6 (p = 3.73 107) were reduced
with age. In contrast, age-related changes in some acylcarnitines
were characterized by an increase in metabolites (C14,
C16, C18:2), while several shorter acylcarnitines, including C3
(p = 0.028; FDR a = 0.2), C4 (p = 0.001), and C5 (p = 0.001),
were decreased. Lifelong DR protected against some of the per-
turbations to amino acids, including Arg and Lys, and the biogenic
amine carnosine (Table S2). Similar to BAT, DR attenuated age-
related changes in SkM for some glycerophospholipids altered
Figure 2. Impact of Aging versus Diet on the Metabolome in Rats and Humans
(A) x and y axes indicate the value of b for the effect of age and diet, respectively, on each metabolite, shown as individual points. The b values are taken from the
linear model, byi =a+ b1age+ b2diet + ε (see Method Details), with statistical significance (p% 0.05) indicated by color. A negative correlation across metabolites
suggests that the effect of DR on metabolite levels acts opposite to the effect of age on metabolite levels. Metabolites were detected via the Biocrates
AbsoluteIDQ p180 and GC-MS small metabolite screenmodules. The figures indicate a slight but significant negative correlation between age and diet effects for
rat plasma and human serum (GC-MS screen), but not in rat tissues. Furthermore, we generally observed more significant effects on metabolite levels for DR
alone (blue) versus age alone (red) or for both DR and age (green).
(B) Correlation plots between b values of individual metabolites across sample type for plasma, serum, and tissue analytes, as measured via the Biocrates
AbsoluteIDQ p180 kit. Between-tissue comparisons are given for diet (lower diagonal) and age (upper diagonal). Strong correlations were observed among rat
plasma and tissues for the effects of diet but not age. Likewise, a significant correlation was observed in the response to DR between human serum and rat
plasma (p < 0.01).
666 Cell Reports 25, 663–676, October 16, 2018
by age, while the effect of DR closely resembled the effect of age
on other metabolite levels, such as PCaaC38:0, PCaaC40:6, and
PCaeC40:6 (Figures S3C and S3D).
In liver, the metabolites that make up PC2, which were almost
entirely glycerophospholipids, revealed a strong effect of age on
the metabolome, although a diet 3 age interaction was evident
due to the high overlap of DR groups on the PCA plot, irrespec-
tive of age (Figure S4A). A small minority of amino acids (Cit, Thr,
isoleucine [Ile], valine [Val], phenylalanine [Phe], and Pro) were
affected by age per se in the liver, and these changes were
largely unaffected by DR (Figure S4B; Table S5). Meanwhile,
the effect of aging on other lipids was more complex, with glyc-
erophospholipids either significantly increased or decreased,
respectively, while nearly 60% of measured sphingolipids were
increased with age. DR failed to counteract age-related changes
in liver sphingolipids but was able to attenuate changes in
several glycerophospholipids (Figures S4C and S4D; Table S5).
Circulating Sarcosine Is Similarly Modulated by Aging
and DR in Rodents and Humans
We next examined the rat and human metabolome for metabo-
lites demonstrating conserved changes with aging and diet.
Among nearly 400 detected metabolites, only sarcosine was
found to be similarly altered with aging and DR, as determined
by the Biocrates AbsoluteIDQ p180 kit. Specifically, sarcosine
was reduced in circulation with aging per se in rats (p = 0.0002;
FDR a = 0.05) and humans (p = 0.0056; FDR a = 0.15), while DR
per se increased levels in rats (p = 0.0001; FDR a = 0.05) and
humans (p = 0.0059; FDR a = 0.08). Furthermore, DR prevented
the age-related decline in rat plasma sarcosine, maintaining
levels comparable to young animals (interaction p = 0.021) (Fig-
ures 4A and 4B). We further observed that both young and old
Ames dwarf mice had markedly elevated levels of sarcosine in
serum (Figure 4C), a finding that is in agreement with the
enhanced liver GNMT activity previously documented in these
mice (Uthus and Brown-Borg, 2003). Metscape analysis of
metabolite networks confirmed that sarcosine is integral to
metabolite shifts with aging and DR in rats and humans (Figures
4D–4G). In liver, sarcosine levels were relatively unchanged
with aging, but were reduced by DR (Figure 4H). Meanwhile,
GNMT, which is the most abundant methyltransferase in liver
and thought to be a major source of circulating sarcosine, via
the conversion ofS-adenosyl Met (SAM) and glycine toS-adeno-
syl homocysteine (SAH) and sarcosine, demonstrated reduced
Figure 3. Biocrates Metabolomic Analysis in Rat Plasma with Aging and DR
(A) PC1metabolites reveal that while shifts in the plasmametabolome can be discriminated by age, metabolites cluster in similar quadrants with DR, regardless of
age. These features of age and diet were largely driven by glycerophosholipids and to a lesser extent by amino acids and sphingolipids.
(B) Heatmap of all metabolites analyzed illustrating hierarchical clustering of plasma levels with age and diet.
(C) Representative glycerophospholipid metabolites in which a significant age 3 diet interaction was observed. Post hoc comparisons for these metabolites
detected an increase in levels for OAL rats, which were completely attenuated by lifelong DR (n = 8 per group).
(D) Representative sphingolipids in which an age3 diet interaction was observed. Post hoc comparisons detected an age-related increase in the levels of these
metabolites, but DR only opposed the increase in SM.C16:0 and SM.C16:1, while DR led to a similar increase in SM.C18:1 levels as age (n = 8 per group). Samples
were measured by single detection, and no coefficient of variation (CV) was calculated for this dataset because a low number of technical replicates (2) were
included in the run. See Table S7 for CVs of the same individual metabolites with the Biocrates assay from 6 technical replicates in a separate run on FBN plasma
samples.
Box and whisker plots represent lower and upper quartile ranges and highest and lowest observations, respectively, and heavy black lines indicate the median.
Dot plots overlaid on boxes represent individual data points. The asterisk indicates significantly different from other experimental groups, p% 0.05.
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expression with aging. Meanwhile, GNMT content (Figure 4I;
p < 0.05) and activity were increased by DR per se (Figure 4J;
age p = 0.396, diet p = 0.021, interaction p = 0.147).
Sarcosine Replacement in Old Animals Alters the
Plasma Metabolome
Next, we aimed to determine whether restoring sarcosine to
more youthful levels could alter the aging metabolome and reca-
pitulate at least some of the DR effects on plasma metabolites.
Old FBN rats were provided either regular chow (control) or a
matched diet supplemented with sarcosine (1,250 mg/kg) for
8 weeks (n = 8 per group). A metabolomic analysis confirmed
that plasma sarcosinewas increased nearly 60%by the diet (Fig-
ure 5A; p < 0.05). However, no effect was observed on body
weight, composition, food intake, and glucose or insulin levels
in old sarcosine-replete rats (Figures 5B–5F). However, PCA re-
vealed that the metabolome from old sarcosine-fed rats was
distinct from controls (Figure 5G) and that global differences
were well visualized by heat cluster map (Figure S5A), with a shift
in a minority of metabolites, including Glu, Trp, Met-sulfoxide
(Met-SO), and several glycerophospholipids, although these
effects were no longer significant after adjusting for the
FDR. Furthermore, using correlations between metabolites to
construct a sarcosine network, a high ‘‘betweenness’’ score
was identified for sarcosine in the linkage of amines, amino
acids, and lipids (Figures 5H and S5B). Glutamate was most
strongly correlated with sarcosine (p < 0.001; Figures 5H, S5B,
and S5C), while sarcosine was also significantly and positively
correlated with the polyamines spermidine (p = 0.034) and sper-
mine (p = 0.034) (FDR a = 0.12; Figures S5B and S5C).
To more specifically examine the relation of sarcosine and age,
as well as the impact of sarcosine replacement on one-carbon
metabolism in old animals, we performed a second refeeding
experiment in aged FBN rats for 4 weeks. Using a fluorescent-
based sarcosine assay in young (4 mo; n = 8), middle-aged
(12 mo; n = 8), old (25–26 mo; n = 10), and old sarcosine-supple-
mented male FBN rats (n = 10), we confirmed that plasma sarco-
sine was similar between young and middle-aged animals but
Figure 4. Sarcosine Is Uniquely Modulated and Integral to the Aging and DR Effects on the Rat and the Human Metabolome
(A and B) Among all of the detected metabolites, only sarcosine levels were similarly reduced with aging and increased by DR in rats (A) and humans (B) (n = 8 per
group for rats; n = 6–7 per group for humans).
(C) Sarcosine is significantly elevated in young and old long-lived Ames dwarf mice (n = 8 per group).
(D–G) Metscape analysis identifies sarcosine as similarly modulated within the metabolite network by aging (blue circle; downregulated) and DR (red circle;
upregulated) in rats (D and E) and humans (F and G).
(H–J) Liver sarcosine is reduced with DR, but not with age (H). Meanwhile, liver GNMT expression decreases with age but is increased by DR (I), while GNMT
activity was numerically decreased with aging and increased by DR (J) (age p = 0.276, diet p = 0.039, age 3 diet p = 0.232).
Box and whisker plots represent lower and upper quartile ranges and highest and lowest observations, respectively, and heavy black lines indicate the median.
Dot plots overlaid on boxes represent individual data points. Metabolomic detection of sarcosine and liver GNMT levels were measured by single detection, and
GNMT activity was measured in duplicate. Bars represent means ± SEMs, n = 8 per group. Brackets with asterisks indicate a significant difference between
groups: *p% 0.05, **p < 0.01, ***p < 0.001. Different letters denote a significant difference between groups, p% 0.05.
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significantly decreased at 25 mo, and this age-related reduction
was restored by sarcosine feeding (Figure 5I; p < 0.05). We next
performed targeted metabolomics in plasma from old control
(n = 10) and old sarcosine-supplemented rats (n = 10) for interme-
diates involved in folate, Met, glycine, and sarcosine metabolism.
We observed that sarcosine led to a significant reduction in
plasma Met levels (Figure 5J; p = 0.04), but it did not alter the
SAM:SAH ratio in plasma or liver (Figure 5K). Sarcosine feeding
did tend to increase plasmaglycine (p = 0.10) andN-acetyl glycine
levels (p = 0.06; Figure S6A), but no effects were observed on
other related plasma metabolites, such as choline, serine,
betaine, or dimethylglycine (Figure S6A).
To better understand to what extent sarcosine levels are
dynamically regulated, including circadian effects and nutrient
availability, we collected serial blood samples from an indwelling
catheter at 4-hr intervals throughout the day in young rats. As
can be observed in Figure S6B, plasma sarcosine levels were
relatively unchanged on average in a 12-hr period, although
some variability was observed across time points in individual
animals (Figure S6C). Furthermore, when samples were
collected under fasted and refed conditions, respectively, there
was no significant effect of nutrient status on sarcosine concen-
trations (Figures S6D and S6E). Thus, these data suggest that the
ability of DR to maintain ‘‘youthful’’ sarcosine levels in old ani-
mals is likely adaptive rather than dynamically regulated by
nutrient availability per se.
Sarcosine Stimulates Autophagic Flux In Vitro and
In Vivo
To determine whether elevated sarcosine may serve as more
than simply a biomarker of aging and DR, we next investigated
whether sarcosine may have direct effects on cellular processes
Figure 5. Sarcosine Refeeding Alters the Old Rat Metabolome and Is an Integral Node Linking Diverse Plasma Metabolites
(A) Sarcosine feeding in aged rats for 8 weeks was able to raise plasma sarcosine levels (n = 8 per group).
(B–F) Sarcosine-fed rats had no significant change in body weight (B), food intake (C), fat mass, lean mass (D), glucose (E), or insulin levels (F) (n = 8 per group).
(G) Despite no effect on gross phenotypic characteristics, PCA confirmed that 8 weeks of sarcosine supplementation in old rats (red) resulted in distinct clustering
of metabolites, as compared to controls (blue), which can be further visualized by heat cluster map (see Figure S5A).
(H) Representative simplified correlation map of sarcosine levels with other metabolites. See Figure S5B for the corresponding detailed correlation map. Sar-
cosine is shown in green, and other metabolites/nodes are shown in blue. The size of the nodes is representative of the number of correlated metabolites at a
given node. Blue interconnecting lines indicate a positive correlation, and red lines indicate a negative correlation. Double lines indicate that a strong correlation
exists between metabolites, as was found with glutamate (p < 0.001). Sarcosine was also positively related to spermine and spermidine (see Figure S5C) and
demonstrated a high ‘‘betweenness’’ score among metabolites.
(I–K) Examination of sarcosine levels across multiple ages confirms that levels do not decline until older age. Furthermore, 4 weeks of sarcosine feeding raised
sarcosine levels in old animals (I), and correspondingly reduced Met levels (J), without effects on the plasma or liver SAM:SAH ratio (K) (n = 8–10 per group).
Sarcosine, liver GNMT levels, and plasma SAM and SAH were measured by single detection, while GNMT activity and liver SAM and SAH were measured in
duplicate.
Box and whisker plots represent the lower and upper quartile ranges and highest and lowest observations, respectively, and heavy white lines indicate the
median. Bars and lines represent means ± SEMs. Dot plots overlaid on boxes represent individual data points. Unless otherwise stated, brackets with asterisks
indicate a significant difference between groups: *p% 0.05, ***p < 0.001.
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implicated in aging. Given the tight connection between meta-
bolism and proteostasis, including the reported inhibitory effect
of SAM levels on autophagy (Sutter et al., 2013), we decided to
determine whether sarcosine could serve to activate autophagy.
We first used NIH 3T3 mouse fibroblasts and two different fluo-
rescent reporters to quantify the activity of the two types of
mammalian autophagy known to decline with age—macroau-
tophagy (mcherry-GFP-LC3) and chaperone-mediated auto-
phagy (CMA, KFERQ-PS-Dendra2) (Kimura et al., 2007; Koga
et al., 2011b). The mCherry-GFP-LC3 reporter is used to label
autophagosomes. As they fuse with lysosomes, GFP fluores-
cence is quenched due to the low lysosomal pH resulting in
mCherry-only labeled autolysosomes. Sarcosine stimulated
basal macroautophagy in a dose-dependent manner and to a
lesser extent macroautophagy induced by serum removal (Fig-
ures 6A and 6B). A separate analysis of changes in the different
vesicular compartments involved in autophagy revealed that
sarcosine enhanced macroautophagy induction (quantified by
autophagic vesicle number) as well as increased efficiency of
lysosomal clearance of autophagosomes, as shown by an
increased number of autolysosomes without a concomitant
increase in autophagosomes (Figures 6C–6E). Analysis of
autophagic flux by quantification of the degradation of the
well-established autophagic cargo p62 also confirmed a dose-
dependent increase in p62 clearance in cells treated with sarco-
sine (Figure 6F). The effect of sarcosine seems to be selective on
macroautophagy rather than a general improvement of all lyso-
somal pathways, since analysis of a second form of autophagy,
CMA, in the same cells did not reveal significant changes in
basal CMA or CMA induced by serum deprivation or oxidative
stress following increasing concentrations of sarcosine (Figures
S7A–S7D). Induction of autophagy by sarcosine was more
discrete than was observed by known inducers such as rapamy-
cin and spermidine, but it was more effective than metformin
(Figure 6G; p < 0.05). Sarcosine (500 mM) showed partially addi-
tive effects on induction of macroautophagy by serum removal
and oxidative stress, suggesting alternative mechanisms of
autophagic activation through sarcosine, compared to these
stressors (Figure 6H). However, sarcosine had no additional ef-
fect upon macroautophagy activation through endoplasmic re-
ticulum (ER) stress or lipid stimuli.
Although identification of the mechanism by which sarcosine
stimulates autophagy is beyond the scope of the present study,
considering the close connections between nutrition and auto-
phagy and the key role that the mechanistic target of rapamycin
(mTOR) plays in both processes, we next analyzed the status of
mTOR signaling (Figures 6I and 6J). In treated cells, we found a
trend toward increased mTOR phosphorylation and TOR com-
plex 1 (TORC1) signaling (using pS6 as a readout), without
noticeable changes in TORC2 (pAktSer473 levels). TORC1 is a
well-established macroautophagy inhibitor during nutrient suffi-
ciency, in part through direct phosphorylation of the autophagy
effector Ulk1 at Ser 757, thus preventing its interaction with the
activating kinase 50 adenosine monophosphate-activated
protein kinase (AMPK) (Kim et al., 2011). Despite higher
TORC1 activity, sarcosine-treated cells displayed significantly
higher phosphorylation of Ulk at Ser 555, one of the AMPK sites
(Figures 6I and 6J). These results suggest that sarcosine is able
to stimulate macroautophagy over a background of enhanced
mTOR signaling, likely by potentiating the stimulatory effect of
AMPK on macroautophagy.
Finally, we determined whether sarcosine can activate in vivo
autophagy in the liver of old rats fed a standard chow diet or a
sarcosine-supplemented diet for 10 days. Sarcosine-treated an-
imals displayed lower levels of the autophagic cargo p62 and
showed increased autophagic flux (measured as both clearance
of LC3-II and p62) in the liver (Figure 7A). Furthermore, electron
microscopy and morphometric analysis revealed similar
numbers of autophagic vacuoles in the livers from both groups
of rats but a significantly higher abundance of autolysosomes
and reduced autophagosome content in sarcosine-supple-
mented animals (Figures 7B and S7E). In fact, autophagosomes
containing high-density lipofuscin pigment (indicative of poor
degradation) were highly abundant in the control group but rarely
observed in the sarcosine-fed animals (Figure S7E), while the
percentage of vacuoles that matured into autolysosomes
increased from <30% to >70% after only 10 days of sarcosine
supplementation (Figure 7B). Thus, induction of macroautoph-
agy by sarcosine also occurs in vivo and does not seem
restricted to a specific cell type. Supporting that the beneficial ef-
fect of sarcosine treatment was coming to a large extent through
serum, incubation of 3T3 cells with heat-inactivated serum from
old sarcosine-treated rats led to less inhibition of autophagy, as
compared to old control rat serum (Figure 7C). Moreover, while
sarcosine levels per se do not appear to demonstrate a discern-
ible diurnal pattern, the ability of sarcosine to activate autophagy
was highly dependent on time of day, because less inhibitory ef-
fects were limited to samples obtained at 9 a.m. and not at later
time points taken throughout the day (Figure S7F). Furthermore,
sarcosine treatment tended to activate a similar signaling
network in liver, as observed in 3T3 cells, evidenced by a strong
induction in pS6 and numerical increase in phospho-AMPK
(pAMPK) (Figures 7D and 7E).
DISCUSSION
Investigations into the metabolism-aging interplay focusing on
changes at the level of the metabolome have been increasingly
reported in a variety of model organisms (Hoffman et al., 2016;
Laye et al., 2015; Lewis et al., 2018; Ma et al., 2015; Pontoizeau
et al., 2014). Studies have also been conducted in humans,
including one report linking several lipid species to human
longevity (Gonzalez-Covarrubias et al., 2013) and another noting
associations among citric acid cycle intermediates and bile
acids on the lifespan in humans (Cheng et al., 2015). However,
arriving at consensus changes that define the agingmetabolome
has proven somewhat elusive, given the inherent complexity of
the metabolome, as well as other variables across studies (De
Guzman et al., 2013; Hoffman et al., 2016; Kim et al., 2014; Ma
et al., 2015). Furthermore, to what extent changes to the aging
metabolome are amenable to interventions such as DR, and
more important, the human relevance of these observations, is
not well understood. Here, we attempted to address some of
these issues using both rodent and human cohorts of aging
and DR. We show that shifts in circulating and tissue glycero-
phospholipids, as well as other lipids and amino acids, define
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the aging rat plasma metabolome, although the directionality of
some changes were distinct from prior reports (Houtkooper
et al., 2011). Furthermore, we found that DR is a stronger driver
of the metabolome than is age, based upon PCA in rat plasma
and tissues. Most important, we identified that the biogenic
amine sarcosine, as similarly modulated by aging and DR in ro-
dents and humans. Moreover, this metabolite is markedly
elevated in dwarf mice and is capable of stimulating macroau-
tophagy in vitro and in vivo.
The growth hormone/insulin-like growth factor-1 (GH/IGF-1)
and mTOR signaling pathways play an integral role in the benefi-
cial effects of DR on aging and longevity (Barzilai et al., 2012;
Fontana et al., 2010b). In addition to a reduction in calories, evi-
dence has also implicated Met restriction as an important medi-
ator of the DR effect (Orentreich et al., 1993; Richie et al., 1994),
and Met interacts with the GH/IGF-1 pathway to extend lifespan
in mice (Brown-Borg et al., 2014). Furthermore, Met is an essen-
tial precursor to SAM, and the conversion of SAM to SAH by
GNMT produces sarcosine (Obata and Miura, 2015). GNMT is
the most abundant methyltransferase in liver and is upregulated
in Ames dwarf mice (Uthus and Brown-Borg, 2003), while GH
replacement can suppress GNMT activity (Aida et al., 1997;
Figure 6. Effect of Sarcosine on Macroautophagy In Vitro
(A) Mouse fibroblasts in culture (NIH 3T3 cells) expressing the tandem reporter mCherry-GFP-LC3 were exposed to the indicated concentrations of sarcosine for
16 hr in the absence or presence of other autophagy inducers. Representative images of both controls and cells treated with 500 mMsarcosine in the presence or
absence of serum are shown.
(B) Quantification of autophagic flux (number of autophagosomesmatured into autolysosomes) at the indicated sarcosine concentrations shows a dose response
to sarcosine (n > 2,500 cells).
(C–E) Number of autophagic vacuoles (AVs; C), autophagosomes (APGs; D) and autolysosomes (AUTs; E) in cells treated with sarcosine (500 mM) show increased
induction (vesicle count) and efficient clearance (AUT/APGs) of APGs (n > 2,500 cells).
(F) Degradation of the autophagic cargo p62 in cells treated with increasing concentrations of sarcosine. Top: representative immunoblot. Bottom: quantification
of the changes in p62 upon addition of lysosomal inhibitors ammonium chloride and leupeptin ammonium chloride and leupeptin (N/L) (n > 4 cells per condition).
(G) A comparative analysis of several well-known inducers of autophagy with sarcosine. Sarcosine is more effective than metformin at inducing autophagy but
less effective than rapamycin and spermidine (n > 2,500 cells). Quantification was done using high-content microscopy. Differences with untreated (‘‘none’’) are
indicated.
(H) Effect of the indicated treatments alone or in combination with 500 mM sarcosine on autophagic flux in cultured mouse fibroblasts. Several methods of
autophagic induction were investigated, including oxidative damage (paraquat [PQ]), ER stress (thapsigargin [TG]) and lipotoxicity (oleic) in addition to serum-
starved induction. Sarcosine showed an additive effect to serum starvation and paraquat, suggesting alternate mechanisms of activation, but not to thapsigargin
or lipotoxicity (n > 2,500 cells).
(I and J) Representative immunoblots (I) and densitometry analysis (J) in 3T3 cells demonstrate that sarcosine activates the mTOR signaling pathway in cells, but
that this occurs in concert with Ulk and LAMP1 activation, suggesting that AMPK activity is also increased, thereby permitting increased autophagy in spite of
mTOR activation.
All results were obtained from a minimum of 3 independent experiments unless otherwise stated. Bars and lines indicate means ± SEMs (n = 3–4 per treatment).
Significantly different from control: *p < 0.05, **p < 0.01, and ***p < 0.001.
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Brown-Borg et al., 2005). Overexpression of GNMT increased
lifespan inD.melanogaster (Obata andMiura, 2015), while knock
down of GNMT resulted in reduced levels of sarcosine and abro-
gated the ability of DR to extend lifespan (Obata and Miura,
2015). These studies serve to illustrate the integral nature of the
Met pathway, including modulation of Met, SAM, SAH, and sar-
cosine by GNMT in longevity. In agreement with this, our results
show that DRper se preserves circulating sarcosine levels during
aging and boosts liver GNMT expression and activity. It is impor-
tant to note that while liver was used here as a surrogate tissue
due to its high concentration of sarcosine-producing enzymes,
GNMT is also expressed elsewhere, albeit at lower levels (Luka
et al., 2009); thus, the relative contribution of liver versus other tis-
sues as the source of circulating sarcosine with aging and diet
perturbations will require further study. In addition, the markedly
elevated sarcosine levels found in dwarfmice suggest that sarco-
sine may be an important component of the longevity phenotype
in this model and across nature. The latter observation is in
agreement with recent studies, not only in D. melanogaster
(Obata and Miura, 2015) but also in aged mice (Kim et al., 2014).
Several recent studies have investigated the relation between
sarcosine and a variety of diseases and disorders in humanswith
conflicting results. Elevated sarcosine levels in urine (Sreekumar
et al., 2009) and serum (Koutros et al., 2013) have been
Figure 7. Effect of Sarcosine on Macroautophagy In Vivo
(A) Autophagic flux increases in rat liver after short-term (10 days) dietary sarcosine feeding. Treatment with the inhibitors of lysosomal proteolysis (20 mM
ammonium chloride and 100 mm leupeptin; N/L) revealed that degradation of LC3 and p62 in lysosomes was accelerated in the sarcosine-treated group.
Representative immunoblot (left) and quantification of the levels and flux of LC3 and p62 (right) are both shown. n = 3 per group.
(B) Effect of a short-term (10 days) dietary sarcosine treatment on the autophagic compartments in aged rat liver. Low-magnification images (left) and examples of
the autophagic compartments more abundant in each of the groups (APGs in untreated and autolysosomes [AUTs] in sarcosine treated). Red arrows indicate
AUTs, and yellow arrows indicate APGs. Quantification of the number of AVs, APGs, AUTs and lysosomes (LYSs) per section (left) and the percentage of AVs that
display characteristics of APGs or AUTs (right) are shown. Data reveal improved maturation of APGs into AUTs after sarcosine treatment, which is indicative of
increased autophagic flux (n = 20 sections from 3 different animals). More examples of each compartment are shown in Figure S7E.
(C) Effect of old control and sarcosine-treated rat serum on autophagy. Heat-inactivated serum collected from old control or sarcosine-treated rats at 9 a.m. was
added to the culture media of NIH 3T3 cells stably expressing the autophagy reporter mCherry-GFP-LC3. Cells were imaged, and the number per cell of AVs
(mCherry+ vesicles), APGs (mCherry+ and GFP+ vesicles), and AUTs (ALs, mCherry+ GFP vesicles) were quantified using high-content microscopy (n > 2,500
cells). Differences with controls (supplemented with serum from untreated rats) were significant at most serum concentrations tested.
(D and E) Evaluation of signaling pathway activation in old rat liver following a short-term (10 days) dietary sarcosine treatment, as demonstrated by representative
western blots (D) and the corresponding densitometry measurements (E), revealed that sarcosine increased pS6 in vivo, while a tendency toward increased
activation of Akt and AMPK was observed (n = 8 per group).
All results were obtained from a minimum of 3 independent experiments unless otherwise stated. Lines and bars indicate means ± SEMs. Significantly different
from controls: *p < 0.05, **p < 0.01, and ***p < 0.001.
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associated with prostate cancer progression, although this rela-
tion has not been observed in other reports (de Vogel et al., 2014;
Jentzmik et al., 2011). Elevated urine sarcosine levels were also
associated with incident type 2 diabetes (Svingen et al., 2016),
while low levels of sarcosine in blood have been linked with
advanced arteriosclerosis (Hasokawa et al., 2012) and several
neurological disorders, including neuropathic pain (Barthel
et al., 2014), cerebral ischemia (Pinto et al., 2014), seizure (So-
ca1a et al., 2010), and Parkinson disease (Tsai et al., 2014).
More recently, serum sarcosine was shown to be increased by
a 10-week aerobic exercise training program in previously un-
trained male subjects (Felder et al., 2017).
While sarcosine has been associated with various diseases
and disorders, it is less clear whether sarcosine per se is a cause
or simply a consequence in these instances. In support of the
former possibility, sarcosine supplementation in humans has
produced promising results as a primary therapy for Parkinson’s
diseasewith dementia (Tsai et al., 2014) and as an adjuvant treat-
ment for patients suffering from schizophrenia (Strzelecki et al.,
2015; Tsai et al., 2004). Likewise, beneficial effects of sarcosine
have been found for learning and memory deficits (Kumar et al.,
2016) and depression in rats (Chen et al., 2017). While sarcosine
feeding in this study did not alter energy balance or endocrine
status in aged rats, it did lead to discrete changes in the rat me-
tabolome, including a reduction in plasma Met and a tendency
toward boosting glycine pools. Sarcosine was also positively
correlated with glutamate as well as spermidine and spermine,
and SAM is involved in the biosynthesis of these polyamines.
However, because no effect on the SAM:SAH ratio was de-
tected, it is not entirely clear whether the reduction in Met by sar-
cosine feeding was in fact due to alterations in SAMmetabolism
or less homocysteine being recycled back to Met. However, the
lack of changes in cysteine, betaine, and dimethylglycine levels
does not support the latter possibility.
In addition to our identification of sarcosine as a biomarker of
aging and DR, our data also demonstrate that this metabolite
can impinge on pathways that are critical to proteostasis and
directlymodulatemacroautophagy in vitroand in vivo. Autophagy
and proteostasis decline with aging in several tissues (Kaushik
and Cuervo, 2015; Madeo et al., 2015; Schneider et al., 2015)
and can be modulated by related metabolites such as Met and
SAM(Ruckenstuhl et al., 2014;Zubiete-Francoetal., 2016),which
have been shown to inhibit autophagy (Sutter et al., 2013). We
observed that sarcosine can directly stimulate basal macroau-
tophagy in a dose-dependent manner in vitro and that this effect
was recapitulated in vivo by sarcosine feeding, as demonstrated
byan increase in autophagicfluxand theclearanceof autophago-
somes and autophagic-like structures filled with lipofuscin-like
dense material that accumulates in aged livers. Although a com-
plete dissection of the mechanism behind sarcosine-induced
autophagy requires further investigation, it was of interest that
mTOR signaling and the AMPK pathway were both increased in
response to sarcosine feeding. These findings suggest that sar-
cosine may be able to sustain enhanced autophagic flux in the
context of mTOR activation by acting on AMPK, a well-known
enhancer of autophagy. This activation ofmacroautophagy could
contribute to improve proteostasis and increase resistance to
stress, as previously described in DR. Ultimately, whether sarco-
sine supplementation can be harnessed to target some of the
deleterious manifestations of aging through stimulation of auto-
phagy is an intriguing possibility to explore in future studies.
Beyond sarcosine, another important observation was the
overall increase in glycerophospholipids and sphingolipids in
rat plasma with aging, although changes in glycerophospholipid
levels among examined tissues were more complex. Studies
have shown that increased incorporation of unsaturated phos-
pholipids in the membrane lipid bilayer increases with age and
that long-lived species have correspondingly lower levels of un-
saturated fatty acids and a lower peroxidation index than their
shorter-lived counterparts (Jove´ et al., 2013). However, DR pre-
vented the age-related increase of several glycerophospholipids
and sphingolipids in rat plasma, and to a lesser extent, changes
to glycerophospholipids in BAT, SkM, and liver, respectively. In
addition, lower concentrations of sphingolipids have been linked
to healthy aging, because high levels found in plasma have been
associated with disease, senescence, and reduced physical
function (Trayssac et al., 2018; Wennberg et al., 2018). Consis-
tent with this observation, our data show that several sphingoli-
pids in plasma and tissue increased with aging in rodents and
were substantially opposed by DR, although little effect of diet
or age was observed in humans. Furthermore, conserved
changes in metabolites with diet or age in humans were only de-
tected for a minority of metabolites, while serum glycerophos-
pholipids tended to decline rather than increase with age, as
was the case in rodents. Thus, there is a clear heterogeneity
that exists in the metabolomic response to diet and aging across
species, strain, and, likely, sex that will need to be accounted for
in future efforts (Jove´ et al., 2016).
In summary, using a rat model of aging, we have shown that
DR is a robust modulator of the metabolome in plasma and tis-
sues and effectively opposes a significant number of age-related
changes in amino acids, glycerophospholipids, acylcarnitines,
and sphingolipids in plasma and tissue.We have identified circu-
lating sarcosine as a metabolite that is similarly and uniquely
modulated by aging and DR in rats and humans and is dramati-
cally elevated in the serum of long-lived Ames dwarf mice.
Furthermore, supplementation studies in old animals identified
sarcosine as a critical node linking amino acid and lipid meta-
bolism, while mechanistic studies demonstrate sarcosine as a
potent stimulator of basal macroautophagy, implicating an inter-
esting link among aging, growth factors, metabolism, and pro-
teostasis. Thus, these data identify sarcosine, which sits at the
nexus of folate, Met, and glycinemetabolism, as a potential func-
tional biomarker of the aging and DR metabolic phenotype.
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Huffman, PhD (derek.huffman@einstein.yu.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Fischer 344 x Brown Norway (FBN) F1 hybrid male rats were obtained from the NIA aging rodent colony and housed under standard
temperature and photoperiod conditions. For DR studies, young FBN rats were obtained at 3 months of age and assigned to AL
feeding (YAL n = 8) or 40% DR (YDR n = 8), which was gradually imposed over a 3 week period and maintained until 6-7 months
of age. Aged AL and DR FBN rats were obtained at 19 months of age from NIA and were maintained on these regimens until
22-23 months of age. All animals were individually housed and provided a weighed amount of rodent chow (Purina 5001). AL intake
was monitored on a weekly basis by measuring the disappearance of food, while DR animals were provided a weighed amount of
pellets (12 g) each afternoon. Serum from 4 mo and 24 mo old female control and Ames dwarf mice (n = 8 group) were obtained
from the NIA Rodent Tissue Bank. In brief, Ames dwarf mouse serum was separated from whole blood samples collected via
cardiac puncture under anesthesia by CO2 inhalation and stored in 200uL aliquots at80C. For characterizing age-related changes
in sarcosine and sarcosine feeding studies, male FBN rats were obtained at 4, 12 and 24 mo of age, respectively.
In humans, the metabolome was determined for shared metabolomic changes in a similarly designed set of serum samples
obtained following an overnight fast from a well-characterized cohort of relatively younger and older subjects consuming a
Western Diet (WD) or a self-imposed DR diet, whereby individual Kcal intake was approximately 30% less than that reported in
the WD group for an average of 7-15 years (Fontana et al., 2010a; Soare et al., 2011; Stein et al., 2012). The group characteristics
were as follows: 1) younger WD: n = 6 (5M, 1F), age = 38.0 ± 2.8yrs; 2) younger DR: n = 6 (6M), age = 37.8 ± 2.6yrs; 3) older
Continued
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WD: n = 7 (6M, 1F), age = 64.6 ± 1.6yrs; 4) older DR: n = 7 (5M, 2F) age = 65.0 ± 1.4yrs. All animal experiments were approved by the
Institutional Animal Care and Use Committee at the Albert Einstein College of Medicine. All human studies were approved by the
Institutional Review Board at Washington University in St. Louis.
METHOD DETAILS
Basic physiology characteristics
Beginning at 3 months and 19 months of age, respectively, body weight and food intake were monitored on a weekly basis. Prior to
sacrifice, body composition was determined by quantitative magnetic resonance (qMR; Echo Medical Systems, Houston, TX). At
study completion, animals were fasted at approximately 0800hr for 4-6 hr prior to being anesthetized under isoflurane and sacrificed.
Trunk blood was collected and tissues were rapidly freeze clamped and flash frozen in liquid nitrogen for downstream applications.
Whole blood was collected into K+ EDTA collection tubes and plasma was separated by centrifugation at 1,500 x g at 4C for 15 min
and stored at 80C. Rat plasma insulin was measured by a rat/mouse ELISA (EMD Millipore, Inc) with rat insulin standards. FFA
(Wako, Diagnostics, Richmond, VA), TG, and free glycerol (Sigma, St. Louis,MO)were analyzed in technical triplicates using standard
calorimetric assays.
Indirect calorimetry
Energy expenditure, substrate utilization and spontaneous activity were determined by indirect calorimetry as described (Huffman
et al., 2016; Huffman et al., 2007), based upon O2 consumption and CO2 production, using a Rat Oxymax System (Columbus Instru-
ments, Columbus, OH). In brief, YAL and OAL and DR animals (n = 8 per group) were placed into individual cages and allowed to
acclimate for at least 72 hr prior to the experiment. DR animals were provided 12 g of food pellets at 1200h while AL animals
were provided unlimited access to feed. Beginning at 1700h, data were collected over 24 hr, and at 1700h the next day, animals
were fasted overnight to evaluate metabolic fuel switching during energy deprivation.
Sarcosine feeding studies
Sarcosine (N-methyl glycine) was purchased from Sigma (cat#84532) and incorporated into Purina chow 5001 at a concentration of
1250mg/kg (Research Diets, Inc). Control and sarcosine-supplemented diets, respectively, were subsequently provided AL to 24mo
old male FBN rats for either 10 days (short-term experiments) as well as 4 wk and 8 wk chronic studies. Body weight and food intake
weremonitored throughout and body composition was assessed prior to sacrifice by qMR in the 8wk cohort. For some animals in the
10-day feeding cohort, jugular catheters were inserted prior to initiating sarcosine feeding (n = 3) to allow for serial blood collection at
0900h, 1200h, 1500h and 1800h, respectively, in serum collection tubes (Sarstedt Inc; Numbecht, Germany) for later in vitro auto-
phagy studies. At study completion, animals were sacrificed in a similar manner as described for the aging and diet cohort study.
Food was removed at 0800hr for 4-6 hr prior to being anesthetized under isoflurane, and animals were sacrificed for collection of
trunk blood and tissues for analyses. Whole blood was collected into K+ EDTA collection tubes and plasma was separated by centri-
fugation at 1,500 x g for 15 min at 4C and stored at 80C.
In vivo sarcosine regulation studies
In order to more carefully characterize to what extent sarcosine levels may be regulated in vivo, we assessed plasma levels across
several ages from trunk blood obtained following a 4 hr fast using a fluorescent-based sarcosine assay (described below) in Young
(4 mo; n = 8), Middle Aged (12 mo; n = 8) and Old (25-26 mo; n = 10) male FBN rats. In addition, plasma sarcosine levels were eval-
uated in venous blood collected from an indwelling catheter at several time points to characterize levels throughout the day, aswell as
under fed and fasted conditions, in 4-5 mo old FBN male rats. Specifically, animals were sedated with 2% isoflurane for surgical
placement of an indwelling catheter into the right internal jugular vein, similar as described (Huffman et al., 2016). Rats were then
singly housed and treated with analgesic as needed and monitored until body weight returned to within 3% of preoperative levels
(7 days). For time course studies, catheterized animals (n = 8) remained in their home cage and had continuous access to food
and water throughout the day. Venous blood (500uL) was then collected from awake, unstressed rats at 0700, 1100, 1500 and
1900hr, respectively, and plasma was rapidly separated and stored at 80C. For the fasting/re-feeding study, animals were as-
signed to either Control (n = 7) or overnight Fasting (n = 7) conditions. Rats were thenmoved to a clean home cage 1 hr prior to begin-
ning the study, and a baseline venous blood sample was collected at 1700hr. Control animals were then allowed continuous, AL ac-
cess to food and water overnight, while rats assigned to the Fasting group were subjected to an overnight food only deprivation
beginning at 1700h with access to water. At 0900hr, a second venous blood sample was collected, and food was then returned
to the home cage of fasted animals for 3 hr, and a third venous sample was collected at 1200hr after 3hrs refeeding, and plasma
was rapidly separated and stored at 80C for analysis.
Quantitation of SAM and SAH levels in plasma and liver
The SAMmethyl cofactor and its SAHmethyltransferase product were analyzed in plasma by Creative Proteomics Inc. (Shirley, NY).
In brief, plasma samples were spiked with internal standard solution in 0.1% formic acid and then treated with 70% perchloric acid.
Following acid extraction, supernatants were analyzed by HPLC-tMS in themultiple reactionmonitoring (MRM) setting. For liver SAM
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and SAH, analysis was performed by HPLC from acid extracted rat liver samples according to previous described methods
(Wagner et al., 1984), with slight modifications. In brief, frozen livers (250mg) were pulverized and extracted with 1mL 0.2Mperchloric
acid. Samples were then centrifuged and supernatants were diluted 5x with HPLC Buffer A prior to injection (50 mL).
Metabolites were resolved at 40C onto a reverse phase column (Luna C182-HTS, 2.5 mm, 100 A˚, 100 3 2 mm; # 00D-4446-B0,
Phenomenex) using a phosphate/octanesulfonate buffer gradient (Flow 0.30 mL min-1; Time, Buffer A/B percentage: 0–2 min
85/15, 2–14 min 0/100, 14–21 min 0/100, 21–21.5 min 85/15, 21.5–30 min 85/15). Both SAH and SAM were characterized by a
maximum absorption at 256 nm and eluted at 11.39 and 12.76 min, respectively; such detection was linear across a 5–140 pmol
range.
Protein isolation and western blotting
Total protein was mechanically homogenized and extracted with denaturing lysis buffer (150mM NaCl, 50mM Tris-HCl (pH 7.4),
0.25% DOC, 5mM EDTA, 1% Triton X-100, 1mM orthovanadate, 100mM NaF, 5mM Na Pyrophosphate, 1x PIC, and 100uM
PMSF) and protein content was determined using the BCAprotein assay (Sigma, St. Louis,MO) with BSA as a standard, as described
(Mao et al., 2018). Proteins were separated by SDS-PAGE using Bis-Tris stain-free gels (BioRad, Hercules, CA), and total protein was
imaged and quantified to confirm equal loading. Gels were then wet-transferred onto PVDF membranes at 100V constant for 1hr,
blocked with 5% milk or BSA, and incubated with an appropriate primary antibody against GNMT (Abcam #ab203396), mTOR
(Cell Signaling #2983S), p-mTOR (Cell Signaling #5536S), Akt (Cell Signaling #4691L), pAktSer473 (Cell Signaling #9271S), S6
(Cell Signaling #2217S), pS6 (Cell Signaling #5364S), AMPK (Cell Signaling #2532), pAMPK (Cell Signaling #2535), Ulk1 (Cell
Signaling #8054), pUlk (Cell Signaling #5869), LAMP1 (Developmental Studies Hybridoma Bank; 1D4B), or LAMP-2A (Cuervo and
Dice, 1996) overnight at 4C. Following a 1hr incubation with secondary antibody, bands were visualized by chemiluminescence us-
ing either an LAS-3000 Imaging System (Fijufim) for experiments in cells or a BioRad Chemidoc Bioimager for in vivo experiments to
first pixel saturation and densitometry performed using software provided by the manufacturer.
EZ-MTase coupled assay for liver GMNT activity
Liver lysate was mechanically extracted with non-denaturing lysis buffer (150mM NaCl, 20mM Tris-HCl (pH 7.4), 1% Triton X-100,
1mM Orthovanadate, 10mM NaF, 1x PIC, 1mM PMSF) and protein content was determined using the BCA protein assay (Sigma,
St. Louis, MO) with BSA as a standard. GNMT activity within rat liver extracts was quantified using the 1-Step EZ-MTase coupled
assay through its UV-mode of detection (Burgos et al., 2017). The methyltransfer from SAM onto the glycine substrate generates
sarcosine and SAH. The SAH product is further catabolized into S-inosyl-L-homocysteine (SIH) by the deaminase TM0936 and
the decrease of absorbance at 263 nm is reporting on the methyltransfer reaction. Reactions were performed in 96-well plates
(Greiner Bio-One, UV-StarMicroplate #655801) and absorbance was recorded onto a SpectraMaxM5 (Molecular Devices). Amas-
ter mix was combined with increasing volumes of liver extract, and blindedmeasurements were performed in duplicate. Methyltrans-
fer reactions started upon addition of SAM (1.76 mM). Initial rates were plotted against liver extract volumes to yield a linear activity
curve; the slope of this representation (mM h-1 mL-1) was converted into GNMT activity and normalized to the amount of total protein
originally present within liver extract (GNMT activity expressed in picomoles of sarcosine synthesized per minute and per milligram of
total protein: pmol min-1 mg-1) with a Z’-factor of 0.75 (Burgos et al., 2017).
Cells
Mouse fibroblasts (NIH 3T3) were obtained from the American Type Culture Collection (ATCC). Cells were maintained in Dulbecco’s
modified Eagle’s medium (Sigma, St. Louis MO) in the presence of 10% newborn calf serum, 50 mg/ml penicillin and 50 mg/ml strep-
tomycin at 37C with 5% CO2.
Autophagy analysis
Autophagy reporters were generated by transducing intact cells with lentivirus carrying the mCherry-GFP-LC3 tandem construct to
measure macroautophagy activity in vitro (Kimura et al., 2007). Cells were plated on coverslips or glass-bottom 96-well plates and
fluorescence recorded from both channels. Puncta positive for both fluorophores correspond to autophagosomes whereas those
only positive for the red fluorophore correspond to autolysosomes. Autophagic flux was determined as the conversion of autopha-
gosomes (yellow) to autolysosomes (red puncta). To measure CMA activity in intact cells, the photoactivatable KFERQ-PSDendra2
reporter was transduced into cells using lentiviral delivery (Koga et al., 2011a). Cells were photoactivated with a 405nm light emitting
diode (Norlux) for 4min with the intensity of 3.5mA (constant current).
CMA activity was quantified as number of puncta per cell. Autophagy reporters were analyzed using high-content microscopy.
Cells plated in glass-bottom 96-well plates were treated for the indicated times and following fixation, images were acquired using
a high-content microscope (Operetta, Perkin Elmer). Images of 9 different fields per well were captured resulting in an average of
2,500-3,000 cells. Nuclei and puncta were identified using the manufacturer’s software. The number of particles/puncta per cell
was quantified using the ‘‘particle identifier’’ function in the cytosolic region after thresholding in non-saturated images (Kaushik &
Cuervo, 2009; Arias et al., 2015). In all cases, focal plane thickness was set at 0.17 mm and sections with maximal nuclear diameter
were selected for quantification. Values are presented as number of puncta per cell section which, in our acquisition conditions, rep-
resented 10%–20% of the total puncta per cell.
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As an alternative method, macroautophagy flux was also measured as the amount of p62 degraded in lysosomes. Specifically,
cells were treated with 20mM NH4Cl and 100 mM leupeptin for 4 hours and then subjected to SDS-PAGE and immunoblotting for
p62. Where indicated, autophagic flux in rat liver was measured ex vivo as previously described (Schneider et al., 2015). Briefly,
freshly isolated livers were minced in 1mm3 cubes and incubated in DMEM either supplemented with or without 20mM NH4Cl
and 100 mM leupeptin for 2h at 37C. Samples were then subjected to SDS-PAGE and immunoblot for p62 and LC3-II.
Transmission electron microscopy
Electronmicroscopy for liver was done after fixation of liver blocks (1mm3 in size) with 2%paraformaldehyde and 2%gluteraldehyde
in 0.1M sodium cacodylate buffer followed by postfixation staining with 1% osmium tetroxide and 1% uranyl acetate. After dehydra-
tation, resin embedding and ultrathin sectioning, samples were viewed on a JEOL 1200EX transmission electronmicroscope at 80 kV
(JEOL USA, Inc). Morphometric classification of autophagic vacuoles was done following standard criteria(Klionsky et al., 2016). Au-
tophagosomes were distinguished as double membrane vesicles with content of similar density as the surrounding cytosol and
comprised often of recognizable cellular structures. Autophagolysosomes were identified as single or partially double membrane
vesicles of content of lower density than the surrounding cytosol and comprised of amorphous content or partially degraded cellular
structures. In both cases, the limiting membrane had to be denuded of ribosomal particles. Morphometric analysis of autophagic
compartments was done by double-blinded independent observers using a single-category allocation or each vesicle in at least
20 different micrographs per condition.
Metabolite profiling and quantification
For initial metabolomic studies, tissue samples were homogenizedwith 6 fold of 5mMammonium acetate (liver) or 2.5mMammonium
acetate (brown fat and gastrocnemius). After two freeze-thaw cycles, 10uL (plasma, serum, and liver) or 20uL (brown fat and gastroc-
nemius) of extract was used for the Biocrates AbsoluteIDQ p180 kit as described (Bonhoure et al., 2015). The samples were analyzed
with UPLC-MS/MS (Xevo TQ, Waters, Pittsburgh, PA, USA) in the Einstein Stable Isotope and Metabolomics Core according to the
manufacturer’s instructions (BIOCRATES Life Sciences AG, Innsbruck, Austria). In addition, an untargeted small metabolite screen
was performed in human serum and rat plasma by GC/MS using an Agilent 7890a GCwith a Gerstel automatic liner exchange cooled
injection systemCIS 4 PTV injector. Both split and large volume injections (LVI) of the sample weremade. GC/MS conditions were set
based on the Feihn protocol (Kind et al., 2009). Briefly, a 30 m DB-5MS column was used for metabolite separation. The oven pro-
gram was started at 600C, kept for 1min, and raise to 3200C at the rate of 100C/min and kept for 5min. Metabolite identification
was done as described using NIST 11 and Fiehn mass spectral libraries. Pooled QC samples were used to evaluate the analytical
variations based on the coefficient of variation (CV) from typically 6 or more injections.
Metabolites specifically related to folate, Met, glycine, and sarcosine pathways were evaluated in plasma from Old Control (n = 10)
and Old Sarcosine (n = 10) animals following 4wks on diet at the Northwest Metabolomics Research Center. Specifically, samples
were subjected to targeted LC-MS/MS analysis on a system consisting of Shimadzu Nexera XR LC-20AD pumps coupled to a Sciex
6500+ triple quadrupole mass spectrometer. The samples were separated on a Waters XBridge BEH column operated in a HILIC
mode. The MS was operated in a scheduled MRM mode through Analyst v1.6.3. Metabolite concentrations were quanitified using
the Multiquant 3.0 software.
Fluorescent detection of plasma sarcosine
Sarcosine from plasma samples was measured in a single-detection format by fluorescence with a coupled assay (Cell Technology,
Freemont, CA; #SARC100). Briefly, in a 96-well plate (Corning, #3991), the enzyme reaction mixture (sarcosine oxidase and chemical
probe, 50 mL) was added to both sarcosine standards (50 mL; 0-20 mM) and diluted samples (1:5, 50 mL; previously incubated at 60C
for 30 min). After centrifugation (1500 rpm, 2 min), fluorescent signal (545 nm excitation and 585 nm emission) was monitored onto a
SpectraMax M5 plate reader (Molecular Devices).
QUANTIFICATION AND STATISTICAL ANALYSIS
All non-metabolomic, parametric datawere analyzed either by independent samples t test, one-way ANOVA or two-way ANOVA (Age
x Diet). When a significant main effect or interaction term, respectively, was observed, planned contrasts were performed with Tukey
Honest Significant Difference [HSD] method. Longitudinal measures were assessed by two-way repeated-measures ANOVA (Group
x Time) or three-way repeated-measures ANOVA (Age x Diet x Time), respectively, with repeated-measures on time, and within-sub-
ject effects were determined with Greenhous-Geisser adjustment. When a significant interaction term was observed, post hoc
comparisons were performed on the mean difference with Tukey HSD adjustment. All data were analyzed using SPSS (SPSS Inc,
Chicago, IL). Data were log transformed when necessary to ensure normality of distribution. A p% 0.05 was considered statistically
significant for all analyses.
Metabolomic data analysis
For both human and rat populations, age and diet were categorized as dichotomous variables. Data were assigned by diet as
either AL or diet restriction (DR), and by age in humans as younger (range = 27-46yrs) and older (range 58-71yrs), while rats were
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categorized as young (6mo) or old (22-23mo). Analyseswere carried out separately for each sample type (human serum, rat plasma,
rat liver, rat BAT, and rat SkM). Across the entire metabolome, data are log-normally distributed. Accordingly, prior to analysis, all
data were log-transformed. Metabolites with more than two missing values were removed from the dataset. For univariate analysis,
all samples were then centered such that themean of all metabolites within a sample was equal to zero. For eachmetabolite, we then
used a simple linear model,
byi =a+ b1age+ b2diet + ε
to test for significant effects of age and diet on each metabolite, where byi is the predicted value of the i
th metabolite as a function of
diet and age. The sign andmagnitude of the effect of age and DR onmetabolite level is given by b1 and b2, respectively. To determine
whether DR reverses the effect of age onmetabolite levels, we compare b1 and b2 values for all metabolites within a particular sample.
Multivariate analysis was carried out in three stages. First, results from the univariate model were used to construct heatmaps.
Each row represented a sample (clustered by age and diet), and each column represented a metabolite (clustered by statistical sig-
nificance). We then carried out metabolite-set enrichment analysis (MSEA, (Xia and Wishart, 2010)) using the Enrichment Analysis
package in MBROLE 2.0 (Lo´pez-Iba´n˜ez et al., 2016), comparing Human Metabolite Data Base (HMDB) lists for significant age or
diet effects using the Benjamini-Hochberg method (Benjamini et al., 2001). Unless otherwise stated, significance for individual me-
tabolites with p values % 0.05 was determined with an FDR a = 0.1. Where significance depends on a higher FDR, this has been
stated. We also used results from the univariate model described above to construct metabolite networks in Metscape (Karnovsky
et al., 2012).
In a final step for multivariate analysis, we carried out principle component analysis (PCA) using the ord function from the made4
library in R. In this case, we removed any features with more than three missing values. Data were centered and scaled first by sam-
ple, and then by feature. We then imputed missing values using the impute.knn function in the impute library in R. We then used the
topgenes function to identify metabolites with high loadings on significant principle components.
Creation of metabolic networks
To visualize metabolic pathways for both rat and human networks for changes with both age and diet, we used the MetScape 3 app
for Cytoscape (version 3.4.0). Kyoto Encyclopedia of Genes andGenomes (KEGG) IDs, in addition to corresponding p values and fold
changes were uploaded to Cytoscape. MetScape used inputted IDs to create networks where nodes are metabolites and direct
edges indicate reactions converting them. Metabolites that increased were colored red, while decreased metabolites were colored
blue, and significant metabolites were outlined in orange.
DATA AND SOFTWARE AVAILABILITY
All metabolomic data are freely available in Supplemental Files, and all other raw data aswell as the R code files used for data analysis
are available upon request.
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